A major concern during the current severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is the use of immunosuppressive therapies for the treatment of multiple sclerosis (MS) due to an increased risk of contracting SARS-CoV-2 and more severe disease. The Society of Italian Neurologists (SIN) and the Association of British Neurologists (ABN) MS and Neuroimmunology Advisory Group published guidance for the use of disease modifying treatments (DMTs) in MS (Table 1). However, taking into account less conservative viewpoints, the emerging knowledge of the biology of SARS-CoV-2, and, in particular, the role of the immune mechanisms contributing to the disease, we propose modification of these guidelines because it is not clear that immunosuppression is indeed detrimental in people with MS infected with SARS-CoV-2. Thus, we are proposing a more nuanced approach and that the categories of DMTs should be modified based on scientific principles and the biology of severe coronavirus disease 2019 (COVID-19; Table 2).

The immune mechanisms contributing to severe COVID-19 include viral subversion of innate immunity and infection of macrophages, and, if similar to SARS-CoV-2, may trigger apoptosis of leucocytes leading to lymphopenia. The exact mechanisms are as yet unclear but suppression of innate responses due to modulation of IFN production or receptor signaling, and the apoptotic effects of virally encoded proteins have been proposed. Together, these allow widespread viral infection, excessive monocyte/macrophage activation, and, in severe cases, a cytokine storm triggering severe acute respiratory distress syndrome (ARDS). The viral-specific CD8 T cell responses seem to eliminate SARS-CoV-2, whereas viral specific antibodies are probably more important to prevent reinfection and create long-lasting immunity. A direct role of B cells in the destructive COVID-19 pathology is unlikely because people with X-linked agammaglobulinemia recover from the COVID-19 pneumonia and lymphopenia without need of intensive care or oxygen ventilation. In MS, although a single case, ocrelizumab treatment did not augment or prolong COVID-19 symptoms.

Because many of the MS DMTs have been designed to target the adaptive immune response; and for therapeutic effect most likely need to target the memory B cells, it is unlikely that MS DMTs treatment impact on the innate immune responses, although there is some evidence that fingolimod and alemtuzumab impact on the innate immune system. In addition, DMTs do not substantially limit the antibody responses to SARS-CoV-2 and, thus, do not pose a risk in the development of protective neutralizing antibody responses, however, some DMTs will blunt this.

To avoid “throwing the baby out with the bathwater” we recommend revision of the published guidelines in light of the role of the immune response in controlling SARS-CoV-2 infection (see Table 2), the emerging biology of COVID-19, and accumulating case reports. We propose that although administration of some DMTs should be modified, others may well control the pathogenic immune responses during severe COVID-19. For example, although the original guidelines that suggest anti-CD20 therapies may increase the risk of infection, this does not necessarily imply a greater risk of poor outcomes following infection. In addition, most MS-related DMTs do not particularly target the innate immune system and few have any major long-term impact on CD8 T cells to limit protection against COVID-19, perhaps with the exception of alemtuzumab. Importantly, MS DMTs do not generally block immature B cell development, thus allowing antibody production preventing (re)infection, as well as response to vaccines when available. However, we...
recommend adjustments to dosing schedules to reduce the chance of infection.

Apart from the reactivation of herpes infections, the moderate immunosuppression obtained with most MS DMTs rarely leads to problems dealing with viral infections, even in the case of novel viral infections such as dengue fever. With the notable exception of progressive multifocal leukoencephalopathy (PML) and other rare central nervous system (CNS) viral infections in natalizumab treated patients, which can be de-risked by adopting extended interval dosing, would indicate that the initiation and continuation of DMTs in MS does not pose an additional risk of developing more severe COVID-19 to people with MS. However, immunosuppression to treat COVID-19 has been proposed as a rational therapeutic approach. This hypothesis is currently being tested in several trials to evaluate several immunosuppressive therapies for COVID-19, which include fingolimod, an S1P modulator (NCT04280588) and IFNβ

### TABLE 1. SIN and the ABN Guidelines for the DMTs in use for MS during the COVID-19 Pandemic

| At risk category | Class | Trade name | Safe to start treatment | On treatment COVID-19 infection | Mode of action |
|------------------|-------|------------|-------------------------|-------------------------------|---------------|
| Low              | Interferon-Beta | Betaferon, Avonex, Rebif, Plerix | Yes | Continue | Stop | Immunomodulatory (not immunosuppressive), pleiotropic immune effects |
| Low              | Glatiramer acetate | Copaxone | Yes | Continue | Stop | Immunomodulatory (not immunosuppressive), pleiotropic immune effects |
| Low              | Teriflunomide | Aubagio | Yes | Continue | Stop | Dihydro-orotate dehydrogenase inhibitor (reduced de novo pyrimidine synthesis), antiproliferative |
| Low              | Dimethyl fumarate | Tecfidera | Yes | Continue | Stop | Pleiotropic, NRF2 activation, downregulation of NFκB |
| Low              | Natalizumab | Tysabri | Yes | Continue | Stop | Anti-VLA4, selective adhesion molecule inhibitor |
| Low              | S1P modulators | Fingolimod (Gilenya) | Yes | Continue | Stop | Selective S1P modulator, prevents egress of lymphocytes from lymph nodes |
| Intermediate     | Anti-CD20 | Ocrelizumab (Ocrevus) | No (Yes) | Suspend | Delay | Anti-CD20, B-cell depleter |
| High<sup>a</sup> | Cladribine | Mavenclad | No | Suspend | Delay | Deoxyadenosine (purine) analogue, deaminase inhibitor, selective T and B cell depletion |
| High<sup>a</sup> | Alemtuzumab | Lemtrada | No | Suspend | Delay | Anti-CD52, nonselective immune depleter |
| High<sup>a</sup> | HSCT | – | No | – | Delay | Non-selective immune depleter |

<sup>a</sup>Risk refers to acquiring infection during the immunodepletion phase. With postimmune reconstitution, the risk is low.

ABN = Association of British Neurologists; COVID-19 = coronavirus disease 2019; DMT = disease modifying treatment; MS = multiple sclerosis; SIN = Society of Italian Neurologists.

Modified from Coles et al.©

*June 2020*
(NCT04343768, NCT04350671) that are widely used to treat MS. Although the information is only emerging, we anticipate that knowledge arising from registers collating data on people with MS, DMTs, and their responses to SARS-CoV2 infection (e.g., NCT04354519) will support the hypothesis that moderate immunosuppression induced by the DMT used in MS may protect against the development of severe COVID-19 infection, which is contrary to current opinion.

The accumulating real-world data on the susceptibility of people with MS to develop severe COVID-19 being treated with immunosuppressive therapies will allow us to accept or reject this hypothesis.

**Author Contributions**
S.A., D.B., K.S. and G.G. all contributed equally to the literature search and writing and S.J.K. assisted with additional comments and suggestions for the final draft.

**Financial Support**
This study received no funding.

### TABLE 2. Proposed Revised Guidelines

| At risk category | Class | Trade Name | Safe to start treatment | Advice regarding treatment | COVID-19 infection |
|------------------|-------|------------|-------------------------|---------------------------|-------------------|
| Very low         | Interferon-beta | Betaferon, Avonex, Rebif, Plegridy | Yes | Continue | Continue |
| Very low         | Glatiramer acetate | Copaxone | Yes | Continue | Continue |
| Very low         | Cladribine/Alemtuzumab/Mitoxantrone/HSCT | see below | N/A | N/A | N/A |
| Very low         | Teriflunomide | Aubagio | Yes | Continue | Continue |
| Low              | Dimethyl fumarate | Tecfidera | Probably | Continue/Switch if lymphopenia | Continue |
| Low              | Natalizumab (EID) | Tysabri | Yes | Continue | Continue or miss infusion depending on timing |
| Low              | Anti-CD20 | Ocrelizumab (Ocrevus), Ofatumumab, Rituximab, Ublituximab | Probably | Risk assessment - continue or suspend dosing | Temporary suspension of dosing depending on timing |
| Intermediate     | Cladribine | Mavenclad | Probably | Risk assessment - continue or suspend dosing | Temporary suspension of dosing depending on timing |
| Intermediate     | S1P modulators | Fingolimod (Gilenya), Siponimod (Mazen), Ozanimod, Ponesimod | Probably | Continue | Continue or temporary suspension of dosing |
| Intermediate     | Natalizumab (SID) | Tysabri | Yes | Continue, but consider EID | Continue or miss infusion depending on timing |
| High*            | Mitoxantrone | Novatrone | No | Suspend dosing | Suspend dosing |
| High*            | Alemtuzumab | Lemtrada | No | Suspend dosing | Suspend dosing |
| High*            | HSCT | – | No | Suspend dosing | Suspend dosing |

*Risk refers to acquiring infection during the immunodepletion phase. With postimmune reconstitution, the risk is low.
COVID-19 = coronavirus disease 2019; EID = extended interval dosing; HSCT = hematopoietic stem-cell transplant; N/A = not applicable; SID = standard interval dosing.
Potential Conflicts of Interest
No company was involved in the decision to write or was involved in the content of this paper. S.A. and SJK have no conflicts of interest. D.B. received consultancy/speaker fees from: Canbex Therapeutics, Inmunebio, Lundbeck, Merck, Novartis, and Sanofi Genzyme. K.S. has received consultancy, speaker fees from: Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. G.G. has received consultancy, speaker fees, or research support from: Abbvie, Actelion, Atara, Biogen, Canbex Therapeutics, Celgene, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda, and Teva. G.G. has received consultancy, speaker fees, or research support from: Abbvie, Actelion, Atara, Biogen, Canbex Therapeutics, Celgene, MedDay, Merck, Novartis, Roche, Sanofi-Genzyme, Takeda, and Teva, and is the Editor of multiple sclerosis and related disorders.

Sandra Amor, PhD
Pathology Department
VUMC, Amsterdam UMC
Amsterdam, The Netherlands
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
London, UK

David Baker, PhD
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
London, UK

Samia J. Khoury, PhD, MD
Partners Multiple Sclerosis Center, Brigham and Women’s Hospital
Boston, MA USA
Abu Haider Neuroscience Institute, American University of Beirut
Beirut, Lebanon

Klaus Schmierer, PhD, MD
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
London, UK
Clinical Board Medicine (Neuroscience)
The Royal London Hospital, Barts Health NHS Trust
London, UK

Gavin Giovanonni, PhD, MD
Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
London, UK
Clinical Board Medicine (Neuroscience)
The Royal London Hospital, Barts Health NHS Trust
London, UK

References
1. WHO. Coronavirus disease 2019 (COVID-19) situation report – 52. Available at: https://www.who.int/docs/default-source/coronaviruse/20200312-sitrep-52-covid-19. Accessed March 12, 2020.

2. Coles A, Lim M, Giovannoni G, Anderson P, Dorsey-Campbell, Qualne M.ABN guidance on the use of disease-modifying therapies in multiple sclerosis in response to the threat of a coronavirus epidemic. https://cdn.ymaws.com/www.theabn.org/resource /collection/65C334C7-30FA-45DB-93AA-74B83A3A20293/02.04.20_ABN_Guidance_on_DMTs_for_MS_and_COVID19_VERSION 4 April 2nd.pdf. Accessed April 2, 2020.

3. Bradley S, Carrol B, Gerbas, Mason D, Boggild M, Beadnall H, van der Walt A, Lechner-Scott J, Frith J, Hodgkinson S, Reddi S, Macdonnell R, Barnett M, Marriott M, McCombe P, Kilpatrick T, Taylor B, Kemmode A. Advice for patients with multiple sclerosis and related disorders regarding COVID-19 outbreak. https://www.msnz.org.nz/wp-content/uploads/2020/04/Alert-Level-4-Advice-for-people-with-MS-9-April-2020.pdf. Accessed on March 6, 2020.

4. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. J Med Virol. 2020. https://doi.org/10.1002/jmv.25884

5. Xiong Y, Liu Y, Cao L, et al. Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerg Microbes Infect 2020;9:761–770. https://doi.org/10.1080/22221751.2020.1747363

6. Yang Y, Xiong Z, Zhang S, et al. Bcl-xl inhibits T-cell apoptosis induced by expression of SARS coronavirus E protein in the absence of growth factors. Biochem J 2005 Nov 15;392:135–143.

7. Sorensa A, Moratto D, Chiarini M, et al. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol 2020 Apr 22. https://doi.org/10.1111/pai.13263

8. Novi G, Mikulski M, Briano F, et al. COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 2020 Apr 15;42:102120. https://doi.org/10.1016/j.msard.2020.102120

9. Baker D, Marta M, Pryce G, et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 2017;16:41–50.

10. Thomas K, Seh T, Proschmann U, et al. Fingolimod additionally acts as immunomodulator focused on the innate immune system beyond its prominent effects on lymphocyte recirculation. J Neuroinflammation 2017;14:41. https://doi.org/10.1186/s12974-017-0817-6

11. Baker D, Giovannini G. Schmierer marked neutropenia: significant but rare in people with multiple sclerosis after alemtuzumab treatment. Mult Scler Relat Disord 2017 Nov;18:181–183. https://doi.org/10.1016/j.msard.2017.09.028

12. Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221–234.

13. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209–220.

14. Baker D, Herrod SS, Alvarez-Gonzalez C, et al. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol 2017 Aug 1;74:961–969. https://doi.org/10.1001/jamaneurol.2017.0676

15. Fragoso YD, Gama PD, Gomes S, et al. Dengue fever in patients with multiple sclerosis taking fingolimod or natalizumab. Mult Scler Relat Disord 2016 Mar;6:64–65. https://doi.org/10.1016/j.msard.2016.01.005

16. Zhovts Ryerson L, Frohman TC, Foley J, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry 2016 Aug;87:885–889. https://doi.org/10.1136/jnnp-2015-312940

17. Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020 Mar 28;395:1033–1034. https://doi.org/10.1016/S0140-6736(20)30282-0

18. D’Antiga L. Coronaviruses and immunosuppressed patients. The facts during the third epidemic. Liver Transpl 2020. https://doi.org/10.1002/lt.25756

DOI: 10.1002/ana.25770